RXDX-106 Is an orally-available, potent and selective TAM/MET inhibitor demonstrating preclinical efficacy in MET-dependent human malignancies

Aleksandra Franovic, Estelle Martin, Sean Uryu et al.|European Journal of Cancer|2016

Cited by 2